Majsterek I - Search Results

1

PERK Is a Haploinsufficient Tumor Suppressor: Gene Dose Determines Tumor-Suppressive Versus Tumor Promoting Properties of PERK in Melanoma.

Pytel D, Gao Y, Mackiewicz K, Katlinskaya YV, Staschke KA, Paredes MC, Yoshida A, Qie S, Zhang G, Chajewski OS, Wu L, Majsterek I, Herlyn M, Fuchs SY, Diehl JA. Pytel D, et al. Among authors: majsterek i. PLoS Genet. 2016 Dec 15;12(12):e1006518. doi: 10.1371/journal.pgen.1006518. eCollection 2016 Dec. PLoS Genet. 2016. PMID: 27977682 Free PMC article.

2

[Tyrosine kinases. New target of anticancer therapy].

Majsterek I, Pytel D, Błasiak J. Majsterek I, et al. Postepy Biochem. 2005;51(3):251-60. Postepy Biochem. 2005. PMID: 16381169 Review. Polish.

3

Imatinib mesylate (STI571) abrogates the resistance to doxorubicin in human K562 chronic myeloid leukemia cells by inhibition of BCR/ABL kinase-mediated DNA repair.

Majsterek I, Sliwinski T, Poplawski T, Pytel D, Kowalski M, Slupianek A, Skorski T, Blasiak J. Majsterek I, et al. Mutat Res. 2006 Jan 31;603(1):74-82. doi: 10.1016/j.mrgentox.2005.10.010. Epub 2006 Jan 4. Mutat Res. 2006. PMID: 16388976

4

Comparative study of DNA damage, cell cycle and apoptosis in human K562 and CCRF-CEM leukemia cells: role of BCR/ABL in therapeutic resistance.

Pytel D, Wysocki T, Majsterek I. Pytel D, et al. Among authors: majsterek i. Comp Biochem Physiol C Toxicol Pharmacol. 2006 Sep;144(1):85-92. doi: 10.1016/j.cbpc.2006.06.010. Epub 2006 Jun 29. Comp Biochem Physiol C Toxicol Pharmacol. 2006. PMID: 16904383

5

Imatinib (STI571) inhibits DNA repair in human leukemia oncogenic tyrosine kinase-expressing cells.

Majsterek I, Arabski M, Czechowska A, Pytel D, Morawiec Z, Morawiec-Bajda A, Blasiak J. Majsterek I, et al. Z Naturforsch C J Biosci. 2006 Nov-Dec;61(11-12):896-902. doi: 10.1515/znc-2006-11-1219. Z Naturforsch C J Biosci. 2006. PMID: 17294703 Free article.

6

[The role of oncogenic tyrosine kinases in the cellular response to anticancer therapy].

Słupianek A, Pytel D, Majsterek I. Słupianek A, et al. Among authors: majsterek i. Postepy Hig Med Dosw (Online). 2007 Dec 14;61:819-27. Postepy Hig Med Dosw (Online). 2007. PMID: 18097340 Free article. Polish.

7

Tyrosine kinase blockers: new hope for successful cancer therapy.

Pytel D, Sliwinski T, Poplawski T, Ferriola D, Majsterek I. Pytel D, et al. Among authors: majsterek i. Anticancer Agents Med Chem. 2009 Jan;9(1):66-76. doi: 10.2174/187152009787047752. Anticancer Agents Med Chem. 2009. PMID: 19149483 Review.

8

DNA damage and repair of head and neck cancer cells after radio- and chemotherapy.

Rusin P, Walczak A, Zwierzchlejska A, Olszewski J, Morawiec-Bajda A, Kaczmarczyk D, Kusmierczyk K, Garncarek P, Pytel D, Sliwinński T, Majsterek I. Rusin P, et al. Among authors: majsterek i. Z Naturforsch C J Biosci. 2009 Jul-Aug;64(7-8):601-10. doi: 10.1515/znc-2009-7-821. Z Naturforsch C J Biosci. 2009. PMID: 19791515 Free article.

9

Analysis of the expression and polymorphism of APOE, HSP, BDNF, and GRIN2B genes associated with the neurodegeneration process in the pathogenesis of primary open angle glaucoma.

Nowak A, Majsterek I, Przybyłowska-Sygut K, Pytel D, Szymanek K, Szaflik J, Szaflik JP. Nowak A, et al. Among authors: majsterek i. Biomed Res Int. 2015;2015:258281. doi: 10.1155/2015/258281. Epub 2015 Mar 29. Biomed Res Int. 2015. PMID: 25893192 Free PMC article.

10

Tumor progression and the different faces of the PERK kinase.

Pytel D, Majsterek I, Diehl JA. Pytel D, et al. Among authors: majsterek i. Oncogene. 2016 Mar 10;35(10):1207-15. doi: 10.1038/onc.2015.178. Epub 2015 Jun 1. Oncogene. 2016. PMID: 26028033 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

226 results

Search Page

Filters